David Blake, MD
Neurology · Lexington, KYNPI 1295837094
Payments from drug & device makers
Across 177 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$714
- Teva Pharmaceuticals USA, Inc.$523
- E.r. Squibb & Sons, L.L.C.$256
- Biohaven Pharmaceuticals, Inc.$207
- Biogen$196
- Novartis$194
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$2,94289%
- Education$34410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $714 |
| Teva Pharmaceuticals USA, Inc. | 66 | $523 |
| E.r. Squibb & Sons, L.L.C. | 7 | $256 |
| Biohaven Pharmaceuticals, Inc. | 5 | $207 |
| Biogen | 7 | $196 |
| Novartis | 11 | $194 |
| Amgen | 14 | $187 |
| Acadia Pharmaceuticals Inc | 2 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Genentech USA, Inc. | 1 | $122 |
| Genentech, Inc. | 4 | $113 |
| AstraZeneca | 1 | $109 |
| UCB, Inc. | 1 | $98 |
| Johnson & Johnson | 1 | $60 |
| Pfizer | 3 | $52 |
| Grifols USA, LLC | 1 | $31 |
| Medtronic | 1 | $26 |
| Acorda Therapeutics, Inc | 2 | $26 |
| Amneal Pharmaceuticals LLC | 2 | $25 |
| Bristol Myers Squibb | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $14 |
| Aucta Pharmaceuticals, Inc. | 1 | $6 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,311 in reported general payments places this provider in the 50th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 17 | $300,154 |
| GlatopaGlatiramer Acetate | 83 | $238,427 |
| CopaxoneGlatiramer Acetate | 39 | $225,258 |
| FingolimodFingolimod Hcl | 26 | $180,550 |
| RebifInterferon Beta-1a/Albumin | 13 | $143,908 |
| BetaseronInterferon Beta-1b | 13 | $127,430 |
| RytaryCarbidopa/Levodopa | 62 | $123,296 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $105,737 |
| ZeposiaOzanimod Hydrochloride | 11 | $98,841 |
| Dimethyl Fumarate | 64 | $78,821 |
| Emgality PenGalcanezumab-Gnlm | 34 | $40,397 |
| Aimovig AutoinjectorErenumab-Aooe | 42 | $35,060 |
| Dalfampridine ErDalfampridine | 79 | $34,531 |
| Keppra XrLevetiracetam | 26 | $31,664 |
| VimpatLacosamide | 13 | $31,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $31 | $300,15417 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $523 | $225,25839 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil | $25 | $134,061170 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $256 | $98,84111 claims |
| AbbVieQulipta, Ubrelvy, Linzess | $714 | $47,05739 claims |
| UCB, Inc.Vimpat, Briviact | $98 | $46,69624 claims |
| PfizerNurtec Odt | $52 | $20,51714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 210 neurology providers in Kentucky.
Other neurology in Lexington
- Gregory JichaLexington$7.1M
- James WinkleyLexington$1.9M
- John SlevinLexington$984K
- Nicole EvermanLexington$834K
- Zabeen MahuwalaLexington$694K
- Toufic FakhouryLexington$326K
- Jagannadha AvasaralaLexington$177K
- Edward KasarskisLexington$121K
- Meriem Bensalem-OwenLexington$65K
- Zain GuduruLexington$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.